Semnur Pharmaceuticals, Inc. 8-K

What Happened
Semnur Pharmaceuticals, Inc. (SMNR) filed an 8-K reporting that it terminated two material securities purchase agreements related to its 2025 business combination. The PIPE Securities Purchase Agreement (PIPE SPA) with JW Capital Securities Limited (dated Aug 20, 2025) and the Semnur/Biconomy Securities Purchase Agreement (dated Sept 23, 2025) with Biconomy PTE. Ltd were both terminated by notice, effective April 20, 2026. The company completed its business combination and domestication to Delaware on Sept 22, 2025.

Key Details

• PIPE SPA (JW Capital): agreement to purchase 1,250,000 shares at $16.00 per share (total consideration = $20,000,000); no shares were issued under the PIPE SPA before termination.
• Semnur/Biconomy SPA: agreement to sell 6,250,000 shares at $16.00 per share payable in Bitcoin (total consideration = $100,000,000); no shares were issued under this SPA before termination.
• Both agreements were terminated by notices delivered on April 20, 2026; the 8-K was filed and signed by CEO Henry Ji on April 23, 2026.
• These agreements were connected to the Company’s Sept 2025 business combination (Denali Capital Acquisition Corp. and Semnur Inc.).

Why It Matters
For investors, the terminations mean that the potential issuances tied to these agreements did not occur, so the company avoided the immediate dilution that would have resulted from issuing those shares. At the same time, Semnur will not receive the cash or Bitcoin proceeds that would have accompanied those transactions (aggregating $120,000,000 at the agreed $16/share price if fully funded). Investors should note this changes the company’s previously disclosed financing expectations; management did not announce replacement financings in the filing.